Health
Study: Caplacizumab not cost effective for treating thrombotic thrombocytopenic purpura – News-Medical.net
In a new study by Yale Cancer Center researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP)…
In a new study by Yale Cancer Center (YCC) researchers, the drug caplacizumab is shown not to be cost-effective in treating thrombotic thrombocytopenic purpura (TTP) when added to the standard-of-care. The findings are being presented today at the virtual 62nd American Society of Hematology (ASH) Annual Meeting & Exposition.
We performed the first-ever cost effectiveness analysis in acquired TTP and found that the addition of caplacizumab to standard of care treatment is not cost effective at its…
-
Noosa News11 hours agoConsolidated Pastoral Company buys Beetaloo aggregation in historic deal worth more than $300m
-
Business22 hours agoWhat Warren Buffett’s latest portfolio moves say about the market
-
General19 hours agoWotjobaluk Nations Festival marks landmark native title recognition
-
General23 hours agoRabbi Eli Schlanger killed in Bondi terror attack